Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Parathyroid Hormone [PTH (1-34)] and NATPARA in Patients With Hypoparathyroidism

Trial Profile

An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Parathyroid Hormone [PTH (1-34)] and NATPARA in Patients With Hypoparathyroidism

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs Teriparatide (Primary) ; Parathyroid hormone
  • Indications Hypoparathyroidism
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Entera Bio
  • Most Recent Events

    • 10 Dec 2018 Planned End Date changed from 1 Dec 2018 to 21 Dec 2018.
    • 10 Dec 2018 Status changed from recruiting to active, no longer recruiting.
    • 08 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top